Muscle Recovery Peptide Protocol

Each peptide targets distinct aspects of muscle recovery. IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 with a 20-30 hour half-life (versus 12-15 minutes for native IGF-1). It promotes muscle hypertrophy through mTOR activation, satellite cell proliferation and differentiation, and enhanced protein synthesis. BPC-157 supports connective tissue repair through growth factor receptor upregulation (VEGF, FGF) and the FAK-paxillin pathway — particularly relevant for tendon-muscle junction injuries. TB-500 (Thymosin Beta-4 fragment) promotes cellular migration via actin polymerization regulation and reduces inflammation through NF-kB modulation.

Before beginning the protocol, document baseline measurements relevant to muscle recovery research. Record: body weight, body composition (if available), strength benchmarks for key movements, perceived soreness ratings (0-10 scale), recovery time between training sessions, and any areas of specific concern (chronic soreness, old injuries). These baseline data are essential for meaningful comparison.

Literature-based research doses: IGF-1 LR3 at 20-50 mcg per day (subcutaneous or intramuscular, typically post-training), administered for 4-6 weeks with equal off-cycle time. BPC-157 at 250-500 mcg per day (subcutaneous, can be split into 2 daily doses). TB-500 at 2-5 mg twice weekly during loading (4 weeks), then 1-2 mg twice weekly for maintenance. Not all three need to be used simultaneously.

Create a structured administration schedule aligned with training. IGF-1 LR3: administer within 30 minutes post-training on training days. On rest days, administer at a consistent time. BPC-157: administer 1-2 times daily at consistent times, regardless of training schedule. TB-500: administer on designated days (e.g., Monday and Thursday), independent of training timing. Separate injection sites for each compound.

Follow the Subcutaneous Injection Technique Protocol for all compounds. For IGF-1 LR3, some research protocols use intramuscular injection into the trained muscle group — this is a more advanced technique requiring proper anatomical knowledge. For BPC-157 and TB-500, standard abdominal subcutaneous injection is the most common route. Rotate injection sites to prevent lipodystrophy.

During the protocol, track recovery-specific metrics at regular intervals. Weekly assessments: strength performance on benchmark lifts, perceived recovery status (PRS) scale, delayed onset muscle soreness (DOMS) duration and severity, hours of sleep and subjective sleep quality, and any changes in body composition. Monthly assessments: repeat full baseline measurements.

After the planned research period (typically 4-6 weeks for IGF-1 LR3, 8-12 weeks for the healing peptides), compile all tracking data. Compare against baseline for each metric. Note which compounds contributed most to observed changes. Plan the off-cycle period (minimum 4 weeks for IGF-1 LR3 receptor resensitization) and determine whether to modify the protocol for the next cycle.